SG11201503395TA - ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα - Google Patents
ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNαInfo
- Publication number
- SG11201503395TA SG11201503395TA SG11201503395TA SG11201503395TA SG11201503395TA SG 11201503395T A SG11201503395T A SG 11201503395TA SG 11201503395T A SG11201503395T A SG 11201503395TA SG 11201503395T A SG11201503395T A SG 11201503395TA SG 11201503395T A SG11201503395T A SG 11201503395TA
- Authority
- SG
- Singapore
- Prior art keywords
- ifnα
- modulation
- compounds useful
- alkyl amide
- pyrimidine compounds
- Prior art date
Links
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723827P | 2012-11-08 | 2012-11-08 | |
| PCT/US2013/068866 WO2014074670A1 (en) | 2012-11-08 | 2013-11-07 | ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201503395TA true SG11201503395TA (en) | 2015-05-28 |
Family
ID=49667570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201503395TA SG11201503395TA (en) | 2012-11-08 | 2013-11-07 | ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9540333B2 (en) |
| EP (1) | EP2917186B1 (en) |
| JP (1) | JP6266639B2 (en) |
| KR (1) | KR102205914B1 (en) |
| CN (1) | CN104903301B (en) |
| AU (1) | AU2013341195B2 (en) |
| BR (1) | BR112015009798A2 (en) |
| CA (1) | CA2890935A1 (en) |
| EA (1) | EA028052B1 (en) |
| ES (1) | ES2648226T3 (en) |
| IL (1) | IL238605A (en) |
| MX (1) | MX2015005561A (en) |
| SG (1) | SG11201503395TA (en) |
| WO (1) | WO2014074670A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR094452A1 (en) | 2012-11-08 | 2015-08-05 | Bristol Myers Squibb Co | HETEROCYCLIC COMPOUNDS REPLACED WITH AMIDA USEFUL AS MODULATORS OF THE ANSWERS OF IL-12, IL-23 AND / OR INFa |
| AR094537A1 (en) | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | PIRIDIL COMPOUNDS REPLACED WITH USEFUL ALQUILAMIDE AS MODULATORS OF THE ANSWERS OF IL-12, IL-23 AND / OR IFNa |
| ES2702126T3 (en) | 2013-12-10 | 2019-02-27 | Bristol Myers Squibb Co | Imidazopyridazine compounds useful as modulators of responses to IL-12, IL-23 and / or IFN alpha |
| MA46620A (en) * | 2016-10-28 | 2021-05-26 | Bristol Myers Squibb Co | USEFUL HETEROBICYCLIC COMPOUNDS AS MODULATORS OF RESPONSES TO IL-12, IL-23 AND / OR IFN ALPHA |
| JOP20180011A1 (en) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | Perulo derivatives [1, 2-b] pyridazine |
| CN107857754B (en) * | 2018-01-15 | 2018-11-09 | 泰山医学院 | A kind of compound and its application in preparing preventing/treating medicine for treating rheumatoid arthritis |
| AU2019234574A1 (en) | 2018-03-12 | 2020-09-03 | Abbvie Inc. | Inhibitors of tyrosine kinase 2 mediated signaling |
| TWI842978B (en) | 2018-07-13 | 2024-05-21 | 美商基利科學股份有限公司 | Pyrrolo[1,2-b]pyridazine derivatives |
| CA3138473A1 (en) * | 2019-04-30 | 2020-11-05 | Celgene Corporation | Combination therapies comprising apremilast and tyk2 inhibitors |
| EP3944859A1 (en) | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
| IL305165A (en) | 2021-02-19 | 2023-10-01 | Sudo Biosciences Ltd | TYK2 inhibitors and their uses |
| BR112023016614A2 (en) | 2021-02-19 | 2023-11-07 | Sudo Biosciences Ltd | TYK2 INHIBITORS AND USES THEREOF |
| KR20240111312A (en) | 2021-10-25 | 2024-07-16 | 카이메라 쎄라퓨틱스 인코포레이티드 | TYK2 degrader and its uses |
| WO2024257023A1 (en) | 2023-06-14 | 2024-12-19 | Alembic Pharmaceuticals Limited | Tyk2 pseudokinase ligands and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| ES2373226T3 (en) * | 2002-06-28 | 2012-02-01 | Astellas Pharma Inc. | DERIVATIVE OF DIAMINOPIRIMIDINCARBOXAMIDA. |
| KR20050019797A (en) * | 2002-06-28 | 2005-03-03 | 야마노우치세이야쿠 가부시키가이샤 | Diaminopyrimidinecarboxamide derivative |
| TW200626561A (en) * | 2004-09-30 | 2006-08-01 | Tibotec Pharm Ltd | HIV inhibiting 5-substituted pyrimidines |
| ATE540035T1 (en) * | 2004-11-24 | 2012-01-15 | Rigel Pharmaceuticals Inc | SPIRO-2,4-PYRIMIDINEDIAMINE COMPOUNDS AND USES THEREOF |
| KR20080114741A (en) * | 2006-03-30 | 2008-12-31 | 티보텍 파마슈티칼즈 리미티드 | 5-amido-substituted pyrimidines that inhibit HIV |
| BRPI0715418A2 (en) * | 2006-07-21 | 2013-03-26 | Novartis Ag | 2,4-di (arylaminio) pyrimidine-5-carboxamide compounds as inhibitors of jak kinases |
| JP5705720B2 (en) * | 2008-04-16 | 2015-04-22 | ポートラ ファーマシューティカルズ， インコーポレイテッド | 2,6-Diamino-pyrimidin-5-yl-carboxamide as SYK or JAK kinase inhibitor |
| VN29259A1 (en) * | 2008-04-16 | 2012-04-25 | Portola Pharm Inc | 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors |
| US20110071158A1 (en) * | 2009-03-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | New compounds |
| WO2010129802A1 (en) * | 2009-05-06 | 2010-11-11 | Portola Pharmaceuticals, Inc. | Inhibitors of jak |
| JP2012529535A (en) * | 2009-06-12 | 2012-11-22 | ブリストル−マイヤーズ スクイブ カンパニー | Nicotinamide compounds useful as kinase modulators |
| WO2011065800A2 (en) * | 2009-11-30 | 2011-06-03 | 주식회사 오스코텍 | Pyrimidine derivative, method for preparing same and pharmaceutical composition containing same |
| ES2968700T3 (en) * | 2011-04-22 | 2024-05-13 | Signal Pharm Llc | Diaminocarboxamide and diaminocarbonitrile substituted pyrimidines, compositions thereof and methods of treatment therewith |
| AR094452A1 (en) | 2012-11-08 | 2015-08-05 | Bristol Myers Squibb Co | HETEROCYCLIC COMPOUNDS REPLACED WITH AMIDA USEFUL AS MODULATORS OF THE ANSWERS OF IL-12, IL-23 AND / OR INFa |
| AR093403A1 (en) | 2012-11-08 | 2015-06-03 | Bristol Myers Squibb Co | PIRIDIL COMPOUNDS REPLACED WITH USEFUL RENTALS AS MODULATORS OF THE ANSWERS OF IL-12, IL23 AND / OR INFa |
| AR094537A1 (en) | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | PIRIDIL COMPOUNDS REPLACED WITH USEFUL ALQUILAMIDE AS MODULATORS OF THE ANSWERS OF IL-12, IL-23 AND / OR IFNa |
-
2013
- 2013-11-07 SG SG11201503395TA patent/SG11201503395TA/en unknown
- 2013-11-07 EP EP13795913.6A patent/EP2917186B1/en active Active
- 2013-11-07 CA CA2890935A patent/CA2890935A1/en not_active Abandoned
- 2013-11-07 US US14/441,213 patent/US9540333B2/en active Active
- 2013-11-07 ES ES13795913.6T patent/ES2648226T3/en active Active
- 2013-11-07 CN CN201380069688.2A patent/CN104903301B/en active Active
- 2013-11-07 JP JP2015541885A patent/JP6266639B2/en active Active
- 2013-11-07 AU AU2013341195A patent/AU2013341195B2/en not_active Ceased
- 2013-11-07 EA EA201590911A patent/EA028052B1/en not_active IP Right Cessation
- 2013-11-07 WO PCT/US2013/068866 patent/WO2014074670A1/en active Application Filing
- 2013-11-07 KR KR1020157011660A patent/KR102205914B1/en active Active
- 2013-11-07 MX MX2015005561A patent/MX2015005561A/en unknown
- 2013-11-07 BR BR112015009798A patent/BR112015009798A2/en not_active Application Discontinuation
-
2015
- 2015-05-04 IL IL238605A patent/IL238605A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015009798A2 (en) | 2017-07-11 |
| US20150299139A1 (en) | 2015-10-22 |
| EP2917186B1 (en) | 2017-10-18 |
| EP2917186A1 (en) | 2015-09-16 |
| EA201590911A1 (en) | 2015-10-30 |
| WO2014074670A1 (en) | 2014-05-15 |
| ES2648226T3 (en) | 2017-12-29 |
| EA028052B1 (en) | 2017-10-31 |
| IL238605A0 (en) | 2015-06-30 |
| AU2013341195B2 (en) | 2017-09-21 |
| CN104903301B (en) | 2017-08-29 |
| JP2016501185A (en) | 2016-01-18 |
| IL238605A (en) | 2017-05-29 |
| MX2015005561A (en) | 2015-07-23 |
| AU2013341195A1 (en) | 2015-07-02 |
| JP6266639B2 (en) | 2018-01-24 |
| KR102205914B1 (en) | 2021-01-20 |
| US9540333B2 (en) | 2017-01-10 |
| KR20150079678A (en) | 2015-07-08 |
| CN104903301A (en) | 2015-09-09 |
| CA2890935A1 (en) | 2014-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2300025I1 (en) | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn-alpha | |
| IL238605A0 (en) | Alkyl amide-substituted pyrimidine compounds useful in the modulation of il-12, il-23 and/or ifnα | |
| IL238554A0 (en) | Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnα responses | |
| IL253950A0 (en) | Bicyclically substituted uracils and the use thereof | |
| IL245448A0 (en) | Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses | |
| IL235216A0 (en) | Lyophilised and aqueous anti-cd40 antibody formulations | |
| EP3083606A4 (en) | Pyrimidines and use thereof | |
| IL241823B (en) | C. novyi containing compositions and uses thereof in treating solid tumors | |
| EP3046417A4 (en) | Methods of using adipose tissue-derived cells in the modulation of pain and/or fibrosis | |
| EP3036849A4 (en) | Bs and ue, and methods used in the same | |
| EP2747777A4 (en) | Rotavirus preparations with excess calcium ions and high viscosities that ensure vaccine viability at elevated temperatures | |
| AU2013902966A0 (en) | Improvements in shoes and the like |